Compare KLRA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLRA | ADMA |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2026 | 2012 |
| Metric | KLRA | ADMA |
|---|---|---|
| Price | $14.84 | $9.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 719.9K | ★ 1.7M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.35 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | N/A | $22.11 |
| P/E Ratio | ★ N/A | $27.26 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $15.15 | $7.21 |
| 52 Week High | $23.82 | $20.46 |
| Indicator | KLRA | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 50.05 |
| Support Level | N/A | $9.23 |
| Resistance Level | $19.02 | $10.24 |
| Average True Range (ATR) | 1.27 | 0.25 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 4.65 | 23.84 |
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.